SCHEMBL2117856

SCHEMBL2117856

Cc1cccc(N(C(C)c2ccccc2F)S(=O)(=O)c2ccccc2F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.46
HSD11B1 P28845 2/20 0.44
HCRTR2 O43614 1/20 0.40
KAT6A Q92794 1/20 0.39
RAB9A P51151 1/20 0.39
GLA P06280 3/20 0.37
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CNR2 P34972 1/20 0.35
HTR1A P08908 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR7 P34969 1/20 0.35
DRD3 P35462 1/20 0.35
HTR6 P50406 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
LMNA P02545 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249846 0.93 HSD11B1 (0.42) RECQLHSD11B1HCRTR2KAT6ARAB9A
SCHEMBL2120045 0.87 RECQL (0.40) RECQLHSD11B1RAB9AGLAMAPT
SCHEMBL2118908 0.87 TSHR (0.48) RECQLHSD11B1RAB9AGLAMAPT
SCHEMBL2120059 0.84 PSEN1 (0.44) HSD11B1KAT6AMAPTSMN1; SMN2KMT2A
SCHEMBL2119849 0.79 HSD11B1 (0.50) HSD11B1HCRTR2KAT6A
SCHEMBL2120075 0.76 PSEN1 (0.44) HSD11B1MAPTSMN1; SMN2KMT2AALDH1A1
SCHEMBL2117553 0.75 HSD11B1 (0.44) HSD11B1HCRTR2MAPTTP53SMN1; SMN2
SCHEMBL4758890 0.64 MCOLN3 (0.58) HSD11B1GLAKMT2ATDP1KCNA5
SCHEMBL3711033 0.64 PKM (0.47) RECQLHSD11B1HCRTR2GLAMAPT
Hydrochloric Acid SCHEMBL5805301 0.63 MCOLN3 (0.57) HSD11B1GLAKMT2ATDP1KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 RECQL 4671/4885HSD11B1 3399/4885HCRTR2 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.